Legal & General Group Plc Sells 7,065 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Legal & General Group Plc lessened its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 1.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 391,388 shares of the biopharmaceutical company’s stock after selling 7,065 shares during the period. Legal & General Group Plc owned 0.25% of TG Therapeutics worth $11,781,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Bleakley Financial Group LLC bought a new stake in shares of TG Therapeutics during the fourth quarter worth $245,000. Castellan Group bought a new stake in TG Therapeutics during the 4th quarter worth about $8,539,000. Barclays PLC lifted its position in TG Therapeutics by 83.9% during the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock valued at $8,117,000 after purchasing an additional 158,323 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of TG Therapeutics by 60.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock valued at $16,859,000 after purchasing an additional 270,286 shares during the last quarter. Finally, Stratos Wealth Advisors LLC acquired a new stake in shares of TG Therapeutics during the 4th quarter worth approximately $241,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Stock Down 2.1 %

Shares of NASDAQ:TGTX opened at $38.21 on Thursday. The company has a 50 day moving average price of $36.08 and a two-hundred day moving average price of $31.64. The company has a market capitalization of $6.00 billion, a PE ratio of -382.06 and a beta of 2.14. TG Therapeutics, Inc. has a 52 week low of $12.93 and a 52 week high of $43.32. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.08 by $0.07. The business had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. Analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 4th. HC Wainwright restated a “buy” rating and issued a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.